Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
439
archived clinical trials in
Eating Disorder

Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Wake Research Associates, LLC
mi
from
Raleigh, NC
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Wake Research Associates, LLC
mi
from
Raleigh, NC
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Patient Priority Clinical sites, LLC
mi
from
Cincinnati, OH
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Patient Priority Clinical sites, LLC
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Community Research
mi
from
Cincinnati, OH
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Community Research
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Midwest Clinical Research Center
mi
from
Dayton, OH
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Midwest Clinical Research Center
mi
from
Dayton, OH
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Linder Center of Hope
mi
from
Mason, OH
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Linder Center of Hope
mi
from
Mason, OH
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Oregon Center for Clinical Investigations, Inc (OCCI, Inc.)
mi
from
Portland, OR
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Oregon Center for Clinical Investigations, Inc (OCCI, Inc.)
mi
from
Portland, OR
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Oregon Center for Clinical Investigations, Inc. (OCCI, Inc.)
mi
from
Salem, OR
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Oregon Center for Clinical Investigations, Inc. (OCCI, Inc.)
mi
from
Salem, OR
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Lehigh Center for Clinical Research
mi
from
Allentown, PA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Lehigh Center for Clinical Research
mi
from
Allentown, PA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Omega Medical Research
mi
from
Warwick, RI
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Omega Medical Research
mi
from
Warwick, RI
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Radiant Research, Inc.
mi
from
Anderson, SC
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Radiant Research, Inc.
mi
from
Anderson, SC
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Radiant Research
mi
from
Greer, SC
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Radiant Research
mi
from
Greer, SC
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Coastal Carolina Research Center
mi
from
Mount Pleasant, SC
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Coastal Carolina Research Center
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Clinical Neuroscience Solution, Inc
mi
from
Memphis, TN
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Clinical Neuroscience Solution, Inc
mi
from
Memphis, TN
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
FutureSearch Clinical Trials LP
mi
from
Austin, TX
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
FutureSearch Clinical Trials LP
mi
from
Austin, TX
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
FutureSearch Trials of Dallas, LP
mi
from
Dallas, TX
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
FutureSearch Trials of Dallas, LP
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Texas Center for Drug Development, P.A.
mi
from
Houston, TX
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Texas Center for Drug Development, P.A.
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Research Across America
mi
from
Plano, TX
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Research Across America
mi
from
Plano, TX
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Radiant Research, Inc
mi
from
San Antonio, TX
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Radiant Research, Inc
mi
from
San Antonio, TX
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Northwest Clinical Research Center
mi
from
Bellevue, WA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Northwest Clinical Research Center
mi
from
Bellevue, WA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Anxiety and Mood Disorder Center
mi
from
Mississauga,
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Anxiety and Mood Disorder Center
mi
from
Mississauga,
Click here to add this to my saved trials
Evaluating the Brain's Response to Natural Versus Artificial Sweetener in Women Who Have Had an Eating Disorder
The Evaluation of Brain Neuronal Activity in Response to Natural (Sucrose) and Artificial (Sucralose) Taste Stimuli- Does Caloric Content Matter to the Brain?
Status: Enrolling
Updated:  3/7/2016
UCSD Eating Disorders Treatment and Research Center
mi
from
La Jolla, CA
Evaluating the Brain's Response to Natural Versus Artificial Sweetener in Women Who Have Had an Eating Disorder
The Evaluation of Brain Neuronal Activity in Response to Natural (Sucrose) and Artificial (Sucralose) Taste Stimuli- Does Caloric Content Matter to the Brain?
Status: Enrolling
Updated: 3/7/2016
UCSD Eating Disorders Treatment and Research Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Changes in Dopamine Levels Before and After Weight Restoration in People With Anorexia Nervosa
Imaging of Dopamine Systems in Anorexia Nervosa
Status: Enrolling
Updated:  4/6/2016
New York State Psychiatric Institute
mi
from
New York, NY
Changes in Dopamine Levels Before and After Weight Restoration in People With Anorexia Nervosa
Imaging of Dopamine Systems in Anorexia Nervosa
Status: Enrolling
Updated: 4/6/2016
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Status: Enrolling
Updated:  5/2/2016
Northwest Christian University
mi
from
Eugene, OR
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Status: Enrolling
Updated: 5/2/2016
Northwest Christian University
mi
from
Eugene, OR
Click here to add this to my saved trials
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Status: Enrolling
Updated:  5/2/2016
University of Oregon
mi
from
Eugene, OR
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Status: Enrolling
Updated: 5/2/2016
University of Oregon
mi
from
Eugene, OR
Click here to add this to my saved trials
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Status: Enrolling
Updated:  5/2/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Status: Enrolling
Updated: 5/2/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Status: Enrolling
Updated:  5/2/2016
Temple University
mi
from
Philadelphia, PA
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Status: Enrolling
Updated: 5/2/2016
Temple University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Status: Enrolling
Updated:  5/2/2016
University of Texas at Austin
mi
from
Austin, TX
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Status: Enrolling
Updated: 5/2/2016
University of Texas at Austin
mi
from
Austin, TX
Click here to add this to my saved trials
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Status: Enrolling
Updated:  5/2/2016
Southwestern University
mi
from
Georgetown, TX
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Status: Enrolling
Updated: 5/2/2016
Southwestern University
mi
from
Georgetown, TX
Click here to add this to my saved trials
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Status: Enrolling
Updated:  5/2/2016
Drexel University
mi
from
Philadelphia, PA
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students
Status: Enrolling
Updated: 5/2/2016
Drexel University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Smartphone Technology and CBT-GSH in Binge Eaters
Innovative Use of the Noom Monitor Mobile Application for CBT-GSH in Binge Eaters
Status: Enrolling
Updated:  5/2/2016
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Smartphone Technology and CBT-GSH in Binge Eaters
Innovative Use of the Noom Monitor Mobile Application for CBT-GSH in Binge Eaters
Status: Enrolling
Updated: 5/2/2016
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Monoamine Contributions to Neurocircuitry in Eating Disorders
Monoamine Contributions to Neurocircuitry in Eating Disorders
Status: Enrolling
Updated:  5/17/2016
University of California, San Diego
mi
from
San Diego, CA
Monoamine Contributions to Neurocircuitry in Eating Disorders
Monoamine Contributions to Neurocircuitry in Eating Disorders
Status: Enrolling
Updated: 5/17/2016
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Motivating Factors That Play a Role in Bulimia Nervosa
Translational Research on Eating Disorders: Behavioral Assessment of Motivation to Eat
Status: Enrolling
Updated:  5/23/2016
Eating Disorders Clinic, New York State Psychiatric Institute
mi
from
New York, NY
Motivating Factors That Play a Role in Bulimia Nervosa
Translational Research on Eating Disorders: Behavioral Assessment of Motivation to Eat
Status: Enrolling
Updated: 5/23/2016
Eating Disorders Clinic, New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  9/20/2017
Southern California Research
mi
from
Beverly Hills, CA
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 9/20/2017
Southern California Research
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  9/20/2017
Southwestern Research
mi
from
Beverly Hills, CA
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 9/20/2017
Southwestern Research
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  9/20/2017
Pharmacology Research Institute
mi
from
Encino, CA
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 9/20/2017
Pharmacology Research Institute
mi
from
Encino, CA
Click here to add this to my saved trials
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  9/20/2017
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 9/20/2017
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  9/20/2017
Pharmacology Research Institute
mi
from
Newport Beach, CA
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 9/20/2017
Pharmacology Research Institute
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  9/20/2017
PCSD - Feighner Research
mi
from
San Diego, CA
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 9/20/2017
PCSD - Feighner Research
mi
from
San Diego, CA
Click here to add this to my saved trials
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  9/20/2017
Research Across America
mi
from
Santa Ana, CA
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 9/20/2017
Research Across America
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  9/20/2017
Lytle and Weiss, PLLC
mi
from
Denver, CO
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 9/20/2017
Lytle and Weiss, PLLC
mi
from
Denver, CO
Click here to add this to my saved trials
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  9/20/2017
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 9/20/2017
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  9/20/2017
The Segal Institute of Clinical Research
mi
from
North Miami, FL
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 9/20/2017
The Segal Institute of Clinical Research
mi
from
North Miami, FL
Click here to add this to my saved trials
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  9/20/2017
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 9/20/2017
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Click here to add this to my saved trials
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  9/20/2017
Miami Research Associates
mi
from
South Miami, FL
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 9/20/2017
Miami Research Associates
mi
from
South Miami, FL
Click here to add this to my saved trials
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  9/20/2017
Institute for Advanced Medical Research
mi
from
Alpharetta, GA
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 9/20/2017
Institute for Advanced Medical Research
mi
from
Alpharetta, GA
Click here to add this to my saved trials
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  9/20/2017
Neurotrials Research, Inc.
mi
from
Atlanta, GA
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 9/20/2017
Neurotrials Research, Inc.
mi
from
Atlanta, GA
Click here to add this to my saved trials
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  9/20/2017
Capstone Clinical Research
mi
from
Libertyville, IL
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 9/20/2017
Capstone Clinical Research
mi
from
Libertyville, IL
Click here to add this to my saved trials
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  9/20/2017
Goldpoint Clinical Research
mi
from
Indianapolis, IN
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 9/20/2017
Goldpoint Clinical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  9/20/2017
McLean Hospital
mi
from
Belmont, MA
Dasotraline Binge Eating Disorder Study
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 9/20/2017
McLean Hospital
mi
from
Belmont, MA
Click here to add this to my saved trials